Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of GSK's malaria vaccine given with routine vaccines at 6, 7.5, and 9 months, followed by a booster; complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GSK malaria vaccine (candidate, co-administered with measles, rubella and yellow fever vaccines) (unknown)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria, Malaria Vaccines | Phase 3 | Status: COMPLETED | Results posted: 2019-08-29